Back to search results

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

Abroad (travel likely)RecruitingPHASE2

Conditions

Immunoglobulin A Nephropathy (IgAN)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Colorado Kidney Care Nephrology, Denver, Colorado, United States

    Contact: Study coordinator (Leigh Collins) · lcollins@cokidneycare.com
    Contact: Principal Investigator (Laura Kooienga)

  • American Clinical Trials, Acworth, Georgia, United States

    Contact: Study coordinator (Chidi Asuzu) · chidi.asuzu@cowryhealth.com
    Contact: Principal Investigator (Chinedu Nweke)

  • Univ Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States

    Contact: Study coordinator (Christine Zabawa) · christine-zabawa-hamilton@uiowa.edu · +1 319 356 1826
    Contact: Principal Investigator (Lama Noureddine)

  • Inter Med Consultants, Edina, Minnesota, United States

    Contact: Study coordinator (Charlene Newton) · charlene.newton@davita.com
    Contact: Principal Investigator (Jonathan Tolins)

  • Novartis Investigative Site, Serra, Espírito Santo, Brazil

  • Novartis Investigative Site, Botucatu, São Paulo, Brazil

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Munich, Bavaria, Germany

  • Novartis Investigative Site, Hanover, Germany

  • Novartis Investigative Site, Mainz, Germany

  • Novartis Investigative Site, Ranica, BG, Italy

  • Novartis Investigative Site, Brescia, BS, Italy

  • Novartis Investigative Site, Pavia, PV, Italy

  • Novartis Investigative Site, Kawasaki, Kanagawa, Japan

  • Novartis Investigative Site, Miyazaki, Japan

  • Novartis Investigative Site, Lodz, Poland

  • Novartis Investigative Site, Opole, Poland

  • Novartis Investigative Site, Seoul, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Pamplona, Navarre, Spain

  • Novartis Investigative Site, Valencia, Valencia, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Seville, Spain

  • Novartis Investigative Site, Kaohsiung City, Taiwan

  • Novartis Investigative Site, Taipei, Taiwan

Study leads

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)